A Phase 4 interventional study of Celecoxib and Diclofenac + Omeprazole in Osteoarthritis and Arthritis, Rheumatoid, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 195 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.
Among the 14 studies testing celecoxib in Osteoarthritis, this one is the 3rd largest by enrollment, is the only one that started in 2005, is one of 10 in phase 4, and was the 3rd registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 41+
By country, each count listing its studies:
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,484 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 150 across the 14 interventional studies. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 5 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing celecoxib in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Celecoxib
Drug: Diclofenac + Omeprazole
Participants are assigned to one of two groups in parallel for the duration of the study
Drug pages: Diclofenac · Omeprazole
Participants are assigned to one of two groups in parallel for the duration of the study
Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments.
Time frame: 6 month treatment duration
Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)
CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.
Time frame: 6 month treatment duration
Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)
Subjects rated response to question: "Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today?" using a 1 to 5 grading scale where 1=very good and 5=very poor.
Time frame: Month 6/Early Termination (ET)
Number of Subjects With SUs
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.
Time frame: 6 month treatment duration
Number of Subjects With CSULGIEs by History of GD Ulceration
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments.
Time frame: 6 month treatment duration
Number of Subjects With Moderate to Severe Abdominal Symptoms
Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms".
Time frame: 6 month treatment duration
Number of Subjects Withdrawn Due to GI Adverse Events (AEs)
GI AEs were defined using MedDRA SOC "Gastrointestinal Disorders" but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions.
Time frame: 6 month treatment duration
Change From Baseline in Hemoglobin at Month 6/ET
Time frame: Month 6/ET
Change From Baseline in Hematocrit at Month 6/ET
Time frame: Month 6/ET
Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin
A clinically significant decrease from baseline was defined as a fall in hematocrit \> = 10 percentage points and/or hemoglobin \> = 2 g/dL.
Time frame: 6 month treatment duration
Number of Subjects With Hepatic AEs in Gamma Glutamyl-Transferase (GGT), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) of 3 Times the Upper Limit of Normal (ULN)
GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males.
Time frame: 6 month treatment duration
Change From Baseline in Hepatic Measures of GGT, AST or ALT to Month 6/ET
Time frame: Month 6/ET
Change From Baseline in Iron Binding Capacity to Month 6/ET
Time frame: Month 6/ET
Change From Baseline in Ferretin to Month 6/ET
Time frame: Month 6/ET
Change From Baseline in C-Reactive Protein to Month 6/ET
Time frame: Month 6/ET
Number of Subjects Alive at the Post Trial Interview
Interview occurred via telephone to obtain follow-up mortality and hospitalization information.
Time frame: 6 months following last dose
Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview
Interview occurred via telephone to obtain follow-up mortality and hospitalization information.
Time frame: 6 months following last dose
| Milestone | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Started | 2238 | 2246 |
| Received treatment | 2223 | 2237 |
| Completed | 1730 | 1621 |
| Not completed | 508 | 625 |
| Withdrew: Adverse event | 233 | 305 |
| Withdrew: Laboratory abnormality | 9 | 33 |
| Withdrew: Lack of efficacy | 21 | 26 |
| Withdrew: Lost to follow-up | 29 | 32 |
| Withdrew: Other | 87 | 76 |
| Withdrew: Withdrawal by subject | 112 | 142 |
| Withdrew: Randomized but did not receive treatment | 15 | 9 |
| Withdrew: Death | 2 | 2 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) | 20 | 81 |
CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs) | 25 | 92 |
Subjects rated response to question: "Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today?" using a 1 to 5 grading scale where 1=very good and 5=very poor.
| scores on a scale | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET) | 0.754 ± 0.020 | 0.773 ± 0.019 |
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Number of Subjects With SUs | 5 | 11 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| History of GD Ulceration (n=395, 400) | 7 | 13 |
| No History of GD Ulceration (n=1843, 1846) | 13 | 68 |
Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms".
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Number of Subjects With Moderate to Severe Abdominal Symptoms | 132 | 162 |
GI AEs were defined using MedDRA SOC "Gastrointestinal Disorders" but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Number of Subjects Withdrawn Due to GI Adverse Events (AEs) | 114 | 167 |
| grams (g)/deciliter (dL) | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Change From Baseline in Hemoglobin at Month 6/ET | -0.017 ± 0.019 | -0.423 ± 0.019 |
| percent | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Change From Baseline in Hematocrit at Month 6/ET | -0.306 ± 0.059 | -1.425 ± 0.059 |
A clinically significant decrease from baseline was defined as a fall in hematocrit \> = 10 percentage points and/or hemoglobin \> = 2 g/dL.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin | 45 | 123 |
GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| GGT | 26 | 86 |
| AST | 8 | 12 |
| ALT | 13 | 27 |
| IU/L | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| GGT | -2.689 ± 0.591 | 7.455 ± 0.592 |
| AST | -0.901 ± 0.239 | 1.490 ± 0.239 |
| ALT | -1.151 ± 0.364 | 5.213 ± 0.364 |
| microgram (ug)/dL | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Change From Baseline in Iron Binding Capacity to Month 6/ET | 2.517 ± 1.158 | 1.952 ± 1.161 |
| ug/dL | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Change From Baseline in Ferretin to Month 6/ET | -3.396 ± 2.224 | -1.990 ± 2.228 |
| mg/dL | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Change From Baseline in C-Reactive Protein to Month 6/ET | 0.058 ± 0.032 | 0.073 ± 0.032 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Number of Subjects Alive at the Post Trial Interview | 2018 | 2023 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information.
| participants | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview | 82 | 79 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib | — | 61/2,223 (2.7%) | 530/2,223 (23.8%) |
| Oral Diclofenac Plus Omeprazole | — | 61/2,237 (2.7%) | 669/2,237 (29.9%) |
| Event | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/2223 | 4/2237 |
| PyrexiaGeneral disorders | 3/2223 | 1/2237 |
| NauseaGastrointestinal disorders | 1/2223 | 3/2237 |
| Acute myocardial infarctionCardiac disorders | 2/2223 | 2/2237 |
| Duodenal ulcerGastrointestinal disorders | 2/2223 | 0/2237 |
| Gastric ulcerGastrointestinal disorders | 2/2223 | 2/2237 |
| CholelithiasisHepatobiliary disorders | 2/2223 | 2/2237 |
| CellulitisInfections and infestations | 2/2223 | 1/2237 |
| Transient ischaemic attackNervous system disorders | 2/2223 | 0/2237 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/2223 | 0/2237 |
| Event | Celecoxib | Oral Diclofenac Plus Omeprazole |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 79/2223 | 168/2237 |
| DyspepsiaGastrointestinal disorders | 137/2223 | 111/2237 |
| Abdominal pain upperGastrointestinal disorders | 96/2223 | 133/2237 |
| HypertensionVascular disorders | 76/2223 | 84/2237 |
| Haemoglobin decreasedInvestigations | 27/2223 | 72/2237 |
| Oedema peripheralGeneral disorders | 46/2223 | 67/2237 |
| HeadacheNervous system disorders | 66/2223 | 48/2237 |
| NauseaGastrointestinal disorders | 33/2223 | 66/2237 |
| NasopharyngitisInfections and infestations | 55/2223 | 46/2237 |
| GastritisGastrointestinal disorders | 32/2223 | 44/2237 |
| Age, Customized(participants) | Celecoxib | Oral Diclofenac Plus Omeprazole | Total |
|---|---|---|---|
| < 55 years | 176 | 164 | 340 |
| 55 to 59 years | 122 | 113 | 235 |
| 60 to 64 years | 721 | 742 | 1463 |
| 65 to 69 years | 623 | 618 | 1241 |
| 70 to 74 years | 361 | 390 | 751 |
| > = 75 years | 235 | 219 | 454 |
| Sex: Female, Male(Participants) | Celecoxib | Oral Diclofenac Plus Omeprazole | Total |
|---|---|---|---|
| Female | 1848 | 1822 | 3670 |
| Male | 390 | 424 | 814 |
Showing the first 100 of 195 sites across 32 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2005, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →